Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy
Marc A. Rodger,Susan R. Kahn,Philip S. Wells,David A. Anderson,Isabelle Chagnon,Grégoire Le Gal,Susan Solymoss,Mark Crowther,Arnaud Perrier,Richard H. White,Linda M. Vickars,Tim Ramsay,M. T. Betancourt,Michael J. Kovacs +13 more
TLDR
Women with 0 or 1 risk factor may safely discontinue oral anticoagulant therapy after 6 months of therapy following a first unprovoked venous thromboembolism, and this criterion does not apply to men.Abstract:
Background: Whether to continue oral anticoagulant therapy beyond 6 months after an “unprovoked” venous thromboembolism is controversial. We sought to determine clinical predictors to identify patients who are at low risk of recurrent venous thromboembolism who could safely discontinue oral anticoagulants. Methods: In a multicentre prospective cohort study, 646 participants with a first, unprovoked major venous thromboembolism were enrolled over a 4-year period. Of these, 600 participants completed a mean 18-month follow-up in September 2006. We collected data for 69 potential predictors of recurrent venous thromboembolism while patients were taking oral anticoagulation therapy (5–7 months after initiation). During follow-up after discontinuing oral anticoagulation therapy, all episodes of suspected recurrent venous thromboembolism were independently adjudicated. We performed a multivariable analysis of predictor variables ( p Results: We identified 91 confirmed episodes of recurrent venous thromboembolism during follow-up after discontinuing oral anticoagulation therapy (annual risk 9.3%, 95% CI 7.7%–11.3%). Men had a 13.7% (95% CI 10.8%–17.0%) annual risk. There was no combination of clinical predictors that satisfied our criteria for identifying a low-risk subgroup of men. Fifty-two percent of women had 0 or 1 of the following characteristics: hyperpigmentation, edema or redness of either leg; D-dimer ≥ 250 μg/L while taking warfarin; body mass index ≥ 30 kg/m 2 ; or age ≥ 65 years. These women had an annual risk of 1.6% (95% CI 0.3%–4.6%). Women who had 2 or more of these findings had an annual risk of 14.1% (95% CI 10.9%–17.3%). Interpretation: Women with 0 or 1 risk factor may safely discontinue oral anticoagulant therapy after 6 months of therapy following a first unprovoked venous thromboembolism. This criterion does not apply to men. (http://Clinicaltrials.gov trial register number NCT00261014)read more
Citations
More filters
Journal ArticleDOI
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Clive Kearon,Elie A. Akl,Anthony J. Comerota,Paolo Prandoni,Henri Bounameaux,Samuel Z. Goldhaber,Michael E. Nelson,Philip S. Wells,Michael K. Gould,Francesco Dentali,Mark Crowther,Susan R. Kahn +11 more
TL;DR: Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.
Journal ArticleDOI
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report
Clive Kearon,Elie A. Akl,Elie A. Akl,Joseph Ornelas,Allen J. Blaivas,David Jiménez,Henri Bounameaux,Menno V. Huisman,Christopher S. King,Timothy A. Morris,Namita Sood,Scott M. Stevens,Janine R.E. Vintch,Philip S. Wells,Scott C. Woller,Lisa K. Moores +15 more
TL;DR: Recommendations on 12 topics that were in the 9th edition of these guidelines are updated, and 3 new topics are addressed.
Journal ArticleDOI
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more
TL;DR: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Journal ArticleDOI
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Stavros Konstantinides,Adam Torbicki,David Fitzmaurice,Simón J,R. Gibbs,Menno V. Huisman,Marc Humbert,John Lekakis,Nicolas Meneveau,Lars Hvilsted Rasmussen,Thomas H. Schindler,Anton Vonk Noordegraaf,José Luis Zamorano,Maurizio Zompatori +13 more
TL;DR: Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome.
Journal ArticleDOI
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)
Stavros Konstantinides,Guy Meyer,Cecilia Becattini,Héctor Bueno,Geert-Jan Geersing,Veli-Pekka Harjola,Menno V. Huisman,Marc Humbert,Catriona Jennings,David Jiménez,Nils Kucher,Irene M. Lang,Mareike Lankeit,Roberto Lorusso,Lucia Mazzolai,Nicolas Meneveau,Fionnuala Ní Áinle,Paolo Prandoni,Piotr Pruszczyk,Marc Philip Righini,Adam Torbicki,Eric Van Belle,José Luis Zamorano +22 more
TL;DR: Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
References
More filters
Journal ArticleDOI
Antithrombotic therapy for venous thromboembolic disease.
TL;DR: It is shown that patients with symptomatic proximal DVT may benefit from fitted compression stockings for at least 3 months to reduce the incidence of the postthrombotic syndrome, and patients with VTE who receive adequate anticoagulation generally do not die of recurrent disease.
Journal ArticleDOI
The long-term clinical course of acute deep venous thrombosis.
Paolo Prandoni,Anthonie W. A. Lensing,Alberto Cogo,S. Cuppini,Sabina Villalta,Mariarosa Carta,Anna M. Cattelan,P. Polistena,Enrico Bernardi,Martin H. Prins +9 more
TL;DR: The clinical course of a first episode of symptomatic deep venous thrombosis in a large consecutive series of patients who had long-term follow-up was assessed and the potential risk factors for these three outcomes were evaluated.
Journal ArticleDOI
Clinical prediction rules. Applications and methodological standards.
TL;DR: Qualitative standards that can be used to decide whether a prediction rule is suitable for adoption in a clinician's practice are described and applied to 33 reports of prediction rules.
Journal ArticleDOI
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Cohort Study
John A. Heit,David N. Mohr,Marc D. Silverstein,Marc D. Silverstein,Tanya M. Petterson,W. Michael O'Fallon,L. Joseph Melton +6 more
TL;DR: Survival after VTE, and especially after PE+/-DVT, is much worse than reported, and significantly less than expected survival, implying that treatment for the 2 disorders should be different.
Journal ArticleDOI
Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis
Philip S. Wells,David Anderson,Marc A. Rodger,Melissa A. Forgie,Clive Kearon,Jonathan Dreyer,George Kovacs,Michael Mitchell,Bernard Lewandowski,Michael J. Kovacs +9 more
TL;DR: Deep-vein thrombosis can be ruled out in a patient who is judged clinically unlikely to have deep-veIn thromBosis and who has a negative D-dimer test, and ultrasound testing can be safely omitted in such patients.
Related Papers (5)
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more